Skip to Main Content

684

Views

0

CrossRef citations to date

0

Altmetric

Original Research

Leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment

Jorge Mestre-Ferrandiza Department of Economics, Universidad Carlos III, Madrid, SpainView further author information

,

Marcin Czechb Department of Pharmacoeconomics, Institute of Mother and Child, Warsaw, PolandView further author information

,

Josef S. Smolenc Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, AustriaView further author information

,

Paul Cornesd Comparative Outcomes Group, Bristol, UKView further author information

,

Matti S. Aaproe Cancer Center, Clinique de Genolier, Vaud, SwitzerlandView further author information

,

Silvio Danesef Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, ItalyView further author information

,

Stephen Deitchg Life Science Practice, Charles River Associates, London, UKView further author information

,

Hannah Tyldsleyg Life Science Practice, Charles River Associates, London, UKView further author information

,

Will Fosterg Life Science Practice, Charles River Associates, London, UKView further author information

,

Pooja Shahh US Medical Affairs, Pfizer, Collegeville, PA, USAView further author information

,

Mark Latymeri Global Medical Affairs, Biosimilars Portfolio, Pfizer, Sandwich, UKCorrespondence[email protected]
View further author information

&

Arnold G. Vultoj Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, NetherlandsView further author information